Prevalence, characteristics and correlates of a positive-dementia screen in patients on antiretroviral therapy in Bamenda, Cameroon: a cross-sectional study
Open Access
- 15 July 2013
- journal article
- research article
- Published by Springer Nature in BMC Neurology
- Vol. 13 (1) , 86
Abstract
In this study we assess the prevalence, characteristics as well as socio-demographic and clinical correlates of a positive screen for HIV-associated dementia in a group of patients on antiretroviral therapy (ART) in Bamenda, Cameroon. In a cross-sectional study, a structured questionnaire was used to collect data on 400 patients attending the Bamenda Regional Hospital AIDS-treatment Centre. Patients were assessed for neurocognitive function using the International HIV Dementia Scale (IHDS) to assess finger-tapping (FT), alternating hand sequence (AHS) and a 4-word recall (4WR), each scored on a maximum of four. A total of 297 (74%) participants were females. The total IHDS score ranged from 6–12 with a mean of 9.02 and 85% of subjects screened positive for dementia (≤10 on IHDS). Participants performed worst in the AHS assessment with a mean of 2.25 (IQR: 2–3). In multivariable analyses, screening positive for dementia was significantly associated with having primary education or less (aOR: 8.33, 95%CI: 3.85, 16.67), and having HIV symptoms (aOR: 12.16, 95%CI: 3.08, 48.05). A very high proportion of patients on ART screened positive for dementia using the IHDS. This could potentially be an indication of a high prevalence of HIV-associated neurocognitive disorders in this population and or a poor performance of the IHDS in patients on ART. Future studies will need to assess the validity of the IHDS in this population of patients on ART and also evaluate long term outcomes in patients with positive dementia screens.Keywords
This publication has 25 references indexed in Scilit:
- Exploring the Utility of the Montreal Cognitive Assessment to Detect HIV-Associated Neurocognitive Disorder: The Challenge and Need for Culturally Valid Screening Tests in South AfricaThe Clinical Neuropsychologist, 2013
- Validity of an interviewer-administered patient health questionnaire-9 to screen for depression in HIV-infected patients in CameroonJournal of Affective Disorders, 2012
- Screening for HIV-Associated Dementia in South Africa: Potentials and Pitfalls of Task-ShiftingAIDS Patient Care and STDs, 2011
- HIV-1 Effects on Neuropsychological Performance in a Resource-Limited Country, ZambiaAIDS and Behavior, 2011
- HIV-associated neurocognitive disorders in sub-Saharan Africa: a pilot study in CameroonBMC Neurology, 2010
- HIV-associated neurocognitive disorders: is there a hidden epidemic?AIDS, 2010
- HIV-Associated Neurocognitive Disorder: Pathogenesis and Therapeutic OpportunitiesJournal of Neuroimmune Pharmacology, 2010
- Risk factors for HIV-associated neurocognitive disorders (HAND) in sub-Saharan Africa: The case of Yaoundé-CameroonJournal of the Neurological Sciences, 2009
- Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapyHIV Medicine, 2009
- The PHQ-9Journal of General Internal Medicine, 2001